Cipla launches Afrezza, an orally inhaled insulin powder for diabetes patients in India. A needle-free alternative to ...

Fathers exposed to microplastics before conception may be setting their daughters up for metabolic problems later in life.

Manufactured by Connecticut-based biopharmaceutical company MannKind Corporation, Afrezza was first launched in the United ...

Cipla has launched Afrezza, an inhaled rapid-acting insulin for adults with diabetes, after CDSCO approval, and plans an ...

Cipla has launched inhaled insulin powder in India, providing a needle-free alternative for diabetes patients. Approved by ...

Drugmaker Cipla has launched Afrezza (insulin human) inhalation powder, the company said, about a year after the product got ...

Key market opportunities for liraglutide and semaglutide include their growing role in diabetes and obesity treatment due to ...

Researchers warn that spending most of our time indoors could be an overlooked risk factor for metabolic diseases ...

The insulin inhalation powder in Afrezza is available in single-use cartridges and is delivered via an inhaler device.

Randomised trial data show GLP 1 receptor agonists are associated with increased risk of gallbladder and biliary disease, ...

Traditional Chinese Medicine may help improve insulin resistance in polycystic ovary syndrome (PCOS) by restoring gut ...

Boxer Willie Limond died after suffering extreme low blood sugar levels linked to taking a fatal dose of insulin. The Glasgow ...